Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-01-27 Sale | 2026-01-29 4:40 pm | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 72,428 | $32.25 | $2,335,860 | 203,233 (Direct) | View |
| 2026-01-23 Sale | 2026-01-27 5:38 pm | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 72,572 | $33.29 | $2,415,843 | 349,877 (Direct) | View |
| 2026-01-20 Sale | 2026-01-22 5:24 pm | NewAmsterdam Pharma Co N.V. | NAMS | Somaiya Mayur Ian Chief Financial Officer | 100,000 | $32.61 | $3,260,618 | 1,423,794 (Direct) | View |
| 2026-01-07 Sale | 2026-01-09 7:34 pm | NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer | 11,582 | $0 | $0 | 823,859 (Direct) | View |
| 2026-01-05 Sale | 2026-01-07 6:31 pm | NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer | 6,000 | $33.25 | $199,500 | 213,981 (Direct) | View |
| 2026-01-05 Sale | 2026-01-07 6:27 pm | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 2,647 | $33.25 | $88,013 | 77,853 (Direct) | View |
| 2026-01-05 Sale | 2026-01-07 6:27 pm | NewAmsterdam Pharma Co N.V. | NAMS | Somaiya Mayur Ian Chief Financial Officer | 5,118 | $33.25 | $170,174 | 173,382 (Direct) | View |
| 2025-12-23 Sale | 2025-12-29 5:14 pm | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 145,000 | $35.84 | $5,196,741 | 756,934 (Direct) | View |
| 2025-09-15 Purchase | 2025-09-17 5:22 pm | NewAmsterdam Pharma Co N.V. | NAMS | Topper James N Director | 660 | $23.7 | $15,639 | 6,829,524 (Indirect) | View |
| 2025-09-09 Sale | 2025-09-10 5:39 pm | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 150,000 | $25.83 | $3,874,017 | 295,015 (Direct) | View |
| 2025-09-08 Purchase | 2025-09-10 5:19 pm | NewAmsterdam Pharma Co N.V. | NAMS | Topper James N Director | 1,260 | $24.99 | $31,487 | 6,828,864 (Indirect) | View |
| 2025-09-03 Sale | 2025-09-05 5:06 pm | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 18,073 | $25.09 | $453,452 | 15,000 (Direct) | View |
| 2025-08-25 Sale | 2025-08-27 5:08 pm | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 8,269 | $24.86 | $205,567 | 15,000 (Direct) | View |
| 2025-08-21 Sale | 2025-08-25 5:04 pm | NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer | 100,000 | $24.72 | $2,471,640 | 69,302 (Indirect) | View |
| 2025-08-11 Purchase | 2025-08-13 4:49 pm | NewAmsterdam Pharma Co N.V. | NAMS | Topper James N Director | 471 | $23.98 | $11,294 | 6,827,604 (Indirect) | View |
| 2025-07-15 Sale | 2025-07-17 5:19 pm | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer | 98,612 | $21.26 | $2,096,655 | 420,447 (Direct) | View |
| 2025-06-24 Purchase | 2025-06-26 7:41 pm | NewAmsterdam Pharma Co N.V. | NAMS | Topper James N Director | 3,780 | $18.38 | $69,466 | 6,827,133 (Indirect) | View |
| 2025-06-16 Sale | 2025-06-18 4:50 pm | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer | 100,000 | $19.29 | $1,929,141 | 678,143 (Direct) | View |
| 2025-06-16 Purchase | 2025-06-18 4:42 pm | NewAmsterdam Pharma Co N.V. | NAMS | Topper James N Director | 8,584 | $19.5 | $167,381 | 6,823,153 (Indirect) | View |
| 2025-05-15 Sale | 2025-05-19 4:44 pm | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer | 100,000 | $0 | $0 | 494,930 (Direct) | View |
| 2025-04-15 Sale | 2025-04-17 5:41 pm | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer | 100,000 | $0 | $0 | 594,930 (Direct) | View |
| 2025-03-26 Purchase | 2025-03-28 5:36 pm | NewAmsterdam Pharma Co N.V. | NAMS | Topper James N Director | 1,135 | $22.49 | $25,521 | 6,814,569 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2026-01-27 Exercise | 2026-01-29 4:40 pm | N/A 2033-01-01 | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 72,428 | $0 | 203,233 (Direct) | View |
| 2026-01-27 Exercise | 2026-01-29 4:40 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 72,428 | $10.9 | 203,233 (Direct) | View |
| 2026-01-23 Exercise | 2026-01-27 5:38 pm | N/A 2033-01-01 | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 72,572 | $0 | 349,877 (Direct) | View |
| 2026-01-23 Exercise | 2026-01-27 5:38 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 72,572 | $10.9 | 349,877 (Direct) | View |
| 2026-01-20 Exercise | 2026-01-22 5:24 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Somaiya Mayur Ian Chief Financial Officer | 100,000 | $9.26 | 1,423,794 (Direct) | View |
| 2026-01-20 Exercise | 2026-01-22 5:24 pm | N/A 2033-11-01 | NewAmsterdam Pharma Co N.V. | NAMS | Somaiya Mayur Ian Chief Financial Officer | 100,000 | $0 | 1,423,794 (Direct) | View |
| 2026-01-07 Option Award | 2026-01-09 7:34 pm | N/A 2036-01-07 | NewAmsterdam Pharma Co N.V. | NAMS | van der Kamp Hilde Johanna Director | 18,700 | $0 | 25,660 (Direct) | View |
| 2026-01-07 Option Award | 2026-01-09 7:34 pm | N/A 2036-01-07 | NewAmsterdam Pharma Co N.V. | NAMS | Gulfo Adele M. Director | 18,700 | $0 | 29,560 (Direct) | View |
| 2026-01-07 Option Award | 2026-01-09 7:34 pm | N/A 2036-01-07 | NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer | 445,000 | $0 | 823,859 (Direct) | View |
| 2026-01-07 Option Award | 2026-01-09 7:34 pm | N/A 2036-01-07 | NewAmsterdam Pharma Co N.V. | NAMS | Lewis William Director | 18,700 | $0 | 25,660 (Direct) | View |
| 2026-01-07 Option Award | 2026-01-09 7:33 pm | N/A 2036-01-07 | NewAmsterdam Pharma Co N.V. | NAMS | Smither John W Director | 18,700 | $0 | 25,660 (Direct) | View |
| 2026-01-07 Option Award | 2026-01-09 7:33 pm | N/A 2036-01-07 | NewAmsterdam Pharma Co N.V. | NAMS | McKenna Mark C. Director | 18,700 | $0 | 25,660 (Direct) | View |
| 2026-01-07 Option Award | 2026-01-09 7:33 pm | N/A 2036-01-07 | NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director | 18,700 | $0 | 25,660 (Direct) | View |
| 2026-01-07 Option Award | 2026-01-07 6:31 pm | N/A 2036-01-07 | NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer | 140,500 | $0 | 213,981 (Direct) | View |
| 2026-01-07 Option Award | 2026-01-07 6:27 pm | N/A 2036-01-07 | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 65,500 | $0 | 77,853 (Direct) | View |
| 2026-01-07 Option Award | 2026-01-07 6:27 pm | N/A 2036-01-07 | NewAmsterdam Pharma Co N.V. | NAMS | Somaiya Mayur Ian Chief Financial Officer | 140,500 | $0 | 173,382 (Direct) | View |
| 2025-12-23 Exercise | 2025-12-29 5:14 pm | N/A 2032-11-22 | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 145,000 | $0 | 756,934 (Direct) | View |
| 2025-12-23 Exercise | 2025-12-29 5:14 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 140,000 | $10 | 756,934 (Direct) | View |
| 2025-12-26 Exercise | 2025-12-29 5:14 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 5,000 | $10.9 | 756,934 (Direct) | View |
| 2025-09-09 Exercise | 2025-09-10 5:39 pm | N/A 2032-11-22 | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 150,000 | $0 | 295,015 (Direct) | View |
| 2025-09-09 Exercise | 2025-09-10 5:39 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 150,000 | $10 | 295,015 (Direct) | View |
| 2025-09-02 Exercise | 2025-09-04 5:43 pm | N/A 2031-07-06 | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 18,073 | $0 | 33,073 (Direct) | View |
| 2025-07-15 Exercise | 2025-07-17 5:19 pm | N/A 2033-01-01 | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer | 98,612 | $0 | 420,447 (Direct) | View |
| 2025-07-15 Exercise | 2025-07-17 5:19 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer | 98,612 | $10.9 | 420,447 (Direct) | View |
| 2025-06-16 Exercise | 2025-06-18 4:50 pm | N/A 2032-11-22 | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer | 100,000 | $0 | 678,143 (Direct) | View |
| 2025-06-16 Exercise | 2025-06-18 4:50 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer | 78,101 | $10 | 678,143 (Direct) | View |
| 2025-06-16 Exercise | 2025-06-18 4:50 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer | 21,899 | $10.9 | 678,143 (Direct) | View |
| 2025-06-01 Option Award | 2025-06-03 5:02 pm | N/A 2035-06-01 | NewAmsterdam Pharma Co N.V. | NAMS | Marino Michael F III See Remarks | 370,000 | $0 | 370,000 (Direct) | View |
| 2025-06-01 Exercise | 2025-06-03 4:59 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director | 68 | $0 | 28,186 (Direct) | View |
| 2025-05-15 Exercise | 2025-05-19 4:44 pm | N/A 2032-11-22 | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer | 100,000 | $0 | 494,930 (Direct) | View |
| 2025-05-15 Exercise | 2025-05-19 4:44 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer | 100,000 | $10 | 494,930 (Direct) | View |
| 2025-05-01 Option Award | 2025-05-02 4:56 pm | N/A 2035-05-01 | NewAmsterdam Pharma Co N.V. | NAMS | Audet Juliette Berangere See Remarks | 30,000 | $0 | 30,000 (Direct) | View |
| 2025-05-01 Exercise | 2025-05-02 4:55 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director | 69 | $0 | 28,186 (Direct) | View |
| 2025-04-14 Exercise | 2025-04-21 5:41 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director | 69 | $0 | 28,186 (Direct) | View |
| 2025-04-15 Exercise | 2025-04-17 5:41 pm | N/A 2032-11-22 | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer | 100,000 | $0 | 594,930 (Direct) | View |
| 2025-04-15 Exercise | 2025-04-17 5:41 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer | 100,000 | $10 | 594,930 (Direct) | View |
| 2025-04-15 Option Award | 2025-04-17 5:36 pm | N/A 2035-04-15 | NewAmsterdam Pharma Co N.V. | NAMS | Gulfo Adele M. Director | 61,560 | $0 | 61,560 (Direct) | View |
| 2025-03-26 Exercise | 2025-03-28 5:29 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 8,269 | $0 | 31,538 (Direct) | View |
| 2025-03-26 Option Award | 2025-03-28 5:29 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 8,269 | $0 | 31,538 (Direct) | View |
| 2025-03-26 Exercise | 2025-03-28 5:24 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director | 3,102 | $0 | 13,576 (Direct) | View |
| 2025-03-26 Option Award | 2025-03-28 5:24 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director | 3,308 | $0 | 13,576 (Direct) | View |
| 2025-03-26 Exercise | 2025-03-28 5:20 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer | 45,481 | $0 | 294,264 (Direct) | View |
| 2025-03-26 Option Award | 2025-03-28 5:20 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer | 64,783 | $0 | 294,264 (Direct) | View |